CliffBio
small molecule

CYSTADANE

BETAINE

Loss of exclusivity—loss of exclusivity
CompanyRecordati Rare Diseases Inc. →See this company's full patent-cliff portfolio

Drug detail

Brand nameCYSTADANE
Active ingredientBETAINE
Strength1GM/SCOOPFUL
Dosage formFOR SOLUTION
RouteORAL
ModalitySmall molecule
FDA approvalOctober 1996
Marketing statusRX

More from Recordati Rare Diseases Inc.

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

CYSTADANE patent cliff — loss of exclusivity — | CliffBio